4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) is a ATRA derivative, and ATPR can induce MDS remission in vitro by decreasing USO1 and modifying Raf/ERK signaling (Li et al., 2021). This evidence concerns the gene USO1 and myelodysplastic syndrome.